Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

  • Adam Feuerstein

By Adam Feuerstein Jan. 7, 2020

Reprints

Where are all the biotech buyouts?

We’re two days into the real start of 2020, the J.P. Morgan Healthcare Conference is fast approaching, and some of biotech’s most buzzed-about acquisition targets have already been crossed off the “deal imminent” list.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Medical device companies now need to prove to FDA…
Medical device companies now need to prove to FDA they’re protected against cyberattacks
Newly available test strips can detect lethal ‘tranq’ in…
Newly available test strips can detect lethal ‘tranq’ in drug supply
23andMe had devastating news about my health. I wish…
23andMe had devastating news about my health. I wish a person had delivered it
NIH releases data showing more clinical trial sponsors are…
NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
British Columbia to bar Americans from buying Ozempic over…
British Columbia to bar Americans from buying Ozempic over supply concerns

Recommended Stories